P005091

Ubiquitin-specific protease 7 (USP7) inhibitor CAS# 882257-11-6

P005091

Catalog No. BCC1287----Order now to get a substantial discount!

Product Name & Size Price Stock
P005091:10mg $85.00 In stock
P005091:20mg $145.00 In stock
P005091:50mg $340.00 In stock
P005091:100mg $595.00 In stock
Related Products

Quality Control of P005091

Number of papers citing our products

Chemical structure

P005091

3D structure

Chemical Properties of P005091

Cas No. 882257-11-6 SDF Download SDF
PubChem ID 2819993 Appearance Powder
Formula C12H7Cl2NO3S2 M.Wt 348.22
Type of Compound N/A Storage Desiccate at -20°C
Synonyms P5091
Solubility DMSO : 50 mg/mL (143.59 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Chemical Name 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone
SMILES CC(=O)C1=CC(=C(S1)SC2=C(C(=CC=C2)Cl)Cl)[N+](=O)[O-]
Standard InChIKey LKZLGMAAKNEGCH-UHFFFAOYSA-N
Standard InChI InChI=1S/C12H7Cl2NO3S2/c1-6(16)10-5-8(15(17)18)12(20-10)19-9-4-2-3-7(13)11(9)14/h2-5H,1H3
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of P005091

DescriptionSelective inhibitor of ubiquitin-specific protease (USP) 7 (IC50 = 4.2 μM). Displays little-to-no inhibition of other USP variants or proteases such as caspase, cathepsins and serine proteases; exhibits some activity at USP47. Induces elevated p53 and apoptosis in cancer cell lines; displays antiangiogenic activity in vivo.

Protocol

Cell experiment [1]:

Cell lines

NCI-60 human tumor cell line.

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

Growth inhibition: 48 h. Cytotoxic activity: 72 h.Solubilized in 100% (v/v) DMSO at 400-fold the desired final maximum test concentration and stored frozen prior to use.

Applications

P005091 exhibits growth inhibition with GI50 value of 1.82 μM in HL-60(TB) cell line and exhibits broad growth inhibition. In HCT-116 cells, P005091 shows cytotoxic activity with EC50 value of 9.21 μM.

Animal experiment [1]:

Animal models

Severe combined immunodeficient (SCID) mice inoculated subcutaneously with human multiple myeloma tumor cells.

Dosage form

10 mg/kg; intravenously twice a week for three weeks.

Application

In SCID mice, P5091 significantly inhibits human plasmacytoma growth and enhances survival.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Cao P, Weinstock J, Kingsbury WD, et al. Anti-neoplastic compounds, compositions and methods. Patent: US 8680139 B2, 2009.

P005091 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

P005091 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of P005091

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.8717 mL 14.3587 mL 28.7175 mL 57.435 mL 71.7937 mL
5 mM 0.5743 mL 2.8717 mL 5.7435 mL 11.487 mL 14.3587 mL
10 mM 0.2872 mL 1.4359 mL 2.8717 mL 5.7435 mL 7.1794 mL
50 mM 0.0574 mL 0.2872 mL 0.5743 mL 1.1487 mL 1.4359 mL
100 mM 0.0287 mL 0.1436 mL 0.2872 mL 0.5743 mL 0.7179 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on P005091

P005091 is a selective, potent inhibitor of USP7 deubiquitylating activity, which is demonstrated to downregulate claspin and phosphorylation of the DNA checkpoint kinase Chk1, and to synergize with genotoxic agents. USP7, known as herpes-associated-ubiquitin-specificprotease (HAUSP), is a deubiquitylating enzyme that regulates the levels of the oncoprotein HDM2 and its substrate, the tumor suppressor p53. P005091 accelerated the degradation of HDM2, while analogs of the compound induced dose- and time-dependent increases in the protein levels of p53 and p21.What’s more,P005091 induced apoptosis in numerous cancer cell lines, including both p53+/+ and p53-mutant cancer cell lines.

Reference

Jeffrey G Marblestone. Ubiquitin Drug Discovery & Diagnostics 2009 – First Annual Conference. IDrugs. 2009; 12(12):750 – 753.

Featured Products
New Products
 

References on P005091

The multifaceted roles of USP7: new therapeutic opportunities.[Pubmed:21468693]

Cell Biochem Biophys. 2011 Jun;60(1-2):61-8.

The deubiquitylating enzyme USP7 (HAUSP) sits at a critical node regulating the activities of numerous proteins broadly characterized as tumor suppressors, DNA repair proteins, immune responders, viral proteins, and epigenetic modulators. Aberrant USP7 activity may promote oncogenesis and viral disease making it a compelling target for therapeutic intervention. Disclosed drug discovery programs have identified inhibitors of USP7 such as P005091 with cellular proof of concept and anti-proliferative activity in cancer models. Taken together, USP7 inhibitors hold promise as a new strategy for the treatment of disease.

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.[Pubmed:22975377]

Cancer Cell. 2012 Sep 11;22(3):345-58.

Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting toxicities and the development of resistance limit its long-term utility. Here, we show that P5091 is an inhibitor of deubiquitylating enzyme USP7, which induces apoptosis in MM cells resistant to conventional and bortezomib therapies. Biochemical and genetic studies show that blockade of HDM2 and p21 abrogates P5091-induced cytotoxicity. In animal tumor model studies, P5091 is well tolerated, inhibits tumor growth, and prolongs survival. Combining P5091 with lenalidomide, HDAC inhibitor SAHA, or dexamethasone triggers synergistic anti-MM activity. Our preclinical study therefore supports clinical evaluation of USP7 inhibitor, alone or in combination, as a potential MM therapy.

Description

P005091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with an EC50 of 4.2 μM.

Keywords:

P005091,882257-11-6,P5091,Natural Products,DUB, buy P005091 , P005091 supplier , purchase P005091 , P005091 cost , P005091 manufacturer , order P005091 , high purity P005091

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: